STOCK TITAN

Interpace Biosciences Inc Stock Price, News & Analysis

IDXG OTC

Welcome to our dedicated page for Interpace Biosciences news (Ticker: IDXG), a resource for investors and traders seeking the latest updates and insights on Interpace Biosciences stock.

Interpace Biosciences Inc (IDXG) delivers molecular diagnostic innovations that transform cancer risk assessment through advanced mutational analysis. This news hub provides investors and healthcare professionals with essential updates on the company’s scientifically validated testing solutions.

Access real-time announcements covering regulatory milestones, clinical study results, and strategic partnerships. Our curated collection includes press releases on thyroid/pancreatic cancer test developments, technology validations, and operational updates directly impacting diagnostic precision.

Key updates focus on IDXG’s progress in reducing unnecessary surgeries through risk-stratified diagnostics, with verified clinical outcomes. Track developments in genetic marker identification, laboratory accreditations, and peer-reviewed research collaborations.

Bookmark this page for streamlined access to IDXG’s latest advancements in precision medicine. Monitor how their evidence-based approach continues shaping oncology diagnostics while creating long-term stakeholder value.

Rhea-AI Summary

Interpace Biosciences, Inc. announced Q1 2024 financial results with a $10.3 million revenue, a 4% YoY increase, and a 10% test volume growth. Operating expenses decreased by 2%, with income from continuing operations at $0.6 million. The company experienced record test volume, cash collections, and profitability, fuelled by increased adoption of molecular diagnostics tests. Despite a slight decrease in gross profit percentage and adjusted EBITDA, the company maintained a strong financial position with $2.8 million cash balance.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.57%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
38.33%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
20%
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-13%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
34.65%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-44.9%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
150%
Tags
-
Rhea-AI Summary

Interpace Biosciences, Inc. (OTCQX: IDXG) reported Q4 2022 Net Revenue of $8.3 million, down 9% from Q4 2021. The company achieved a 60% Gross Profit percentage, improving from 55% the previous year. Operating income reached $0.1 million, bouncing back from a loss of $(1.4) million in Q4 2021. Loss from continuing operations decreased to $(1.4) million from $(1.7) million. For the full year, Net Revenue was $31.8 million, a 4% decline due to a reimbursement rate drop. However, loss from continuing operations improved to $(5.9) million compared to $(7.0) million in 2021.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.14%
Tags
none
-
Rhea-AI Summary

Interpace Biosciences reported Q3 2022 net revenue of $8.2 million, a 2% increase year-over-year. Adjusted EBITDA was positive at $0.1 million, highlighting operational improvement. Operating expenses were down 12% compared to the previous year, contributing to a loss from continuing operations of $1.3 million, slightly better than Q3 2021. Cash and cash equivalents stood at $6.3 million. Despite challenges from the ThyGeNEXT pricing change, the company noted record testing volumes over the last two quarters.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-12.12%
Tags
none
Rhea-AI Summary

Interpace Biosciences (OTCQX: IDXG) announced new clinical utility data for its ThyGeNEXT® + ThyraMIR®v2 test platform. The findings, presented at the American Thyroid Association (ATA) 2022 Annual Meeting, demonstrate the platform's effectiveness in assessing malignancy risk in indeterminate thyroid nodules (ITN). Key results include improved accuracy, a decreased false-positive rate, and a 70% benign call rate, potentially reducing unnecessary surgeries for patients. CEO Tom Burnell reaffirmed the company's commitment to personalized medicine.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.4%
Tags
none

FAQ

What is the current stock price of Interpace Biosciences (IDXG)?

The current stock price of Interpace Biosciences (IDXG) is $0.7699 as of July 3, 2025.

What is the market cap of Interpace Biosciences (IDXG)?

The market cap of Interpace Biosciences (IDXG) is approximately 5.3M.
Interpace Biosciences Inc

OTC:IDXG

IDXG Rankings

IDXG Stock Data

5.29M
3.42M
25.19%
1.17%
Diagnostics & Research
Healthcare
Link
United States
Parsippany